Randomized double blind placebo-controlled trial of<i>Saccharomyces cerevisiae</i>CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation

Spiller, Robin C.; Pélerin, Fanny; Decherf, Amélie Cayzeele; Maudet, Corinne; Housez, Béatrice; Cazaubiel, Murielle; Jüsten, Peter

doi:10.1177/2050640615602571

Cited by 70 publications

(105 citation statements)

References 28 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our ex vivo perfusion setup may provide a relatively simple, though not high throughput, method to screen yeasts or fungi for beneficial effects on the host intestine. Previously discussed results of S. cerevisiae and S. boulard ii clinical trials further support the therapeutic potential of Saccharomyces yeasts in humans[7,11]. We predict that the beneficial or probiotic potential of fungi and yeasts is set to expand with increased research, initially in animal models followed by human trials.…”

Section: Discussionmentioning

confidence: 70%

“…Suggestive for a potential beneficial role for S. cerevisiae are reports indicating that this strain may provoke immune stimulation in mice infected with Staphylococcus aureus [10]. Supplementation with a S. cerevisiae I-3856 strain may improve symptoms in constipation-predominant irritable bowel syndrome patients[11]. There is also evidence that a S. cerevisiae UFMG 905 strain can bind to bacteria and modulate inflammation pathways in a murine model of Salmonella enterica serovar Typhimurium infection[12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects ofSaccharomyces cerevisiaeorboulardiiyeasts on acute stress induced intestinal dysmotility

West

Stanisz

Wong

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo investigate the capacity of Saccharomyces cerevisiae (S. cerevisiae) and Saccharomyces boulardii (S. boulardii) yeasts to reverse or to treat acute stress-related intestinal dysmotility.METHODSAdult Swiss Webster mice were stressed for 1 h in a wire-mesh restraint to induce symptoms of intestinal dysmotility and were subsequently killed by cervical dislocation. Jejunal and colon tissue were excised and placed within a tissue perfusion bath in which S. cerevisiae, S. boulardii, or their supernatants were administered into the lumen. Video recordings of contractility and gut diameter changes were converted to spatiotemporal maps and the velocity, frequency, and amplitude of propagating contractile clusters (PCC) were measured. Motility pre- and post-treatment was compared between stressed animals and unstressed controls.RESULTSS. boulardii and S. cerevisiae helped to mediate the effects of stress on the small and large intestine. Restraint stress reduced jejunal transit velocity (mm/s) from 2.635 ± 0.316 to 1.644 ± 0.238, P < 0.001 and jejunal transit frequency (Hz) from 0.032 ± 0.008 to 0.016 ± 0.005, P < 0.001. Restraint stress increased colonic transit velocity (mm/s) from 0.864 ± 0.183 to 1.432 ± 0.329, P < 0.001 and frequency to a lesser degree. Luminal application of S. boulardii helped to restore jejunal and colonic velocity towards the unstressed controls; 1.833 ± 0.688 to 2.627 ± 0.664, P < 0.001 and 1.516 ± 0.263 to 1.036 ± 0.21, P < 0.001, respectively. S. cerevisiae also had therapeutic effects on the stressed gut, but was most apparent in the jejunum. S. cerevisiae increased PCC velocity in the stressed jejunum from 1.763 ± 0.397 to 2.017 ± 0.48, P = 0.0031 and PCC frequency from 0.016 ± 0.009 to 0.027 ± 0.007, P < 0.001. S. cerevisiae decreased colon PCC velocity from 1.647 ± 0.187 to 1.038 ± 0.222, P < 0.001. Addition of S. boulardii or S. cerevisiae supernatants also helped to restore motility to unstressed values in similar capacity.CONCLUSIONThere is a potential therapeutic role for S. cerevisiae and S. boulardii yeasts and their supernatants in the treatment of acute stress-related gut dysmotility.

show abstract

Section: Discussionmentioning

confidence: 70%

Section: Introductionmentioning

confidence: 99%

Effects ofSaccharomyces cerevisiaeorboulardiiyeasts on acute stress induced intestinal dysmotility

West

Stanisz

Wong

et al. 2016

WJG

View full text Add to dashboard Cite

show abstract

“…However, recent randomised controlled trials demonstrated no significant benefit of probiotics preparations over placebo in the treatment of pain in adults with IBS44 in contrast to the benefit observed in some (but not all) trials in children with regard to frequency and intensity of abdominal pain, for example, with a combination of three Bifidobacterial species45 or a single bacterial species 46…”

Section: Current Approaches To Manage Visceral Pain In Patients With Ibsmentioning

confidence: 93%

Dietary and pharmacological treatment of abdominal pain in IBS

Camilleri

Boeckxstaens

2017

Gut

119

120

View full text Add to dashboard Cite

This review introduces the principles of visceral sensation and appraises the current approaches to management of visceral pain in functional GI diseases, principally IBS. These approaches include dietary measures including fibre supplementation, low fermentable oligosaccharides, disaccharides, monosaccharides and polyols diet, and pharmacological approaches such as antispasmodics, peppermint oil, antidepressants (tricyclic agents, selective serotonin reuptake inhibitors), 5-HT receptor antagonists (alosetron, ondansetron, ramosetron), non-absorbed antibiotic (rifaximin), secretagogues (lubiprostone, linaclotide), μ-opioid receptor (OR) and κ-OR agonist, δ-OR antagonist (eluxadoline), histamine H1 receptor antagonist (ebastine), neurokinin-2 receptor antagonist (ibodutant) and GABAergic agents (gabapentin and pregabalin). Efficacy and safety are discussed based on pivotal trials or published systematic reviews and meta-analysis, expressing ORs or relative risks and their 95% CIs. Potential new approaches may be based on recent insights on mucosal expression of genes, and microRNA and epigenetic markers in human biopsies and in animal models of visceral hypersensitivity.The objectives of this review are to appraise the physiology and anatomy of gut sensation and the efficacy in the relief of visceral pain (typically in IBS) of several classes of therapies. These include fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and different classes of medications (box 1). Box 1Classes of pharmacological agents for visceral painAntidepressants (tricyclic agents, selective serotonin reuptake inhibitors)Peppermint oil5-HT receptor antagonists (alosetron, ondansetron, ramosetron)Non-absorbed antibiotic (rifaximin)Secretagogues (lubiprostone, linaclotide)μ-Opioid receptor (OR) and κ-OR agonist and δ-OR antagonist (eluxadoline)Histamine H1 receptor antagonist (ebastine)Neurokinin-2 receptor antagonist (ibodutant)GABAergic agents (gabapentin and pregabalin).

show abstract

“…Two randomized clinical trials (RCTs) have been conducted and published[10,11] involving a total of 579 IBS subjects. We decided to perform an individual patient data (IPD) meta-analysis to confirm the previous findings and strengthen conclusions on this particular yeast strain.…”

Section: Introductionmentioning

confidence: 99%

Saccharomyces cerevisiaeCNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis

Cayzeele-Decherf

Pélerin

Leuillet

et al. 2017

WJG

Self Cite

View full text Add to dashboard Cite

AIMTo confirm previous conclusions on Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856 for irritable bowel syndrome (IBS) management.METHODSAn individual patient data meta-analysis was performed on two randomized clinical trials studying the effect of S. cerevisiae CNCM I-3856 supplementation on gastrointestinal (GI) symptoms in IBS subjects. A total of 579 IBS subjects were included. Outcomes were the daily Likert scale scores of abdominal pain/discomfort and bloating [area under the curve (AUC) and weekly means], responder status, and bowel movements (stool frequency and consistency). Statistical analyses were conducted in Intent to Treat (ITT) population, IBS-C subjects and IBS-C subjects with an abdominal pain/discomfort score higher than or equal to 2 at baseline (“IBS-C ≥ 2 subpopulation”).RESULTSS. cerevisiae CNCM I-3856 significantly improved abdominal pain/discomfort and bloating during the second month of supplementation [AUC (W5-W8)] with improvement up to the minimal clinically relevant threshold of 10%: a 12.3% reduction of abdominal pain/discomfort in the ITT population compared to the Placebo group (P = 0.0134) has been observed. In the IBS-C ≥ 2 subpopulation, there were a 13.1% reduction of abdominal pain/discomfort and a 14.9% reduction of bloating compared to the Placebo group (P = 0.0194 and P = 0.0145, respectively). GI symptoms significantly decreased during supplementation but no statistical differences were reported between groups at the end of the supplementation period. Responder status was defined as a subject who experienced a decrease of 1 arbitrary unit (a.u.) or 50% of the abdominal discomfort score from baseline for at least 2 wk out of the last 4 wk of the study. A significant difference between groups was reported in the ITT population, when considering the first definition: subjects in the Active group had 1.510 higher odds to be a responder (reduction of 1 a.u. of abdominal pain/discomfort) compared with subjects in the Placebo group (P = 0.0240). At the end of supplementation period, stool consistency in the Active group of the ITT population was significantly improved and classified as “normal” compared to Placebo (respectively 3.13 ± 1.197 a.u. vs 2.58 ± 1.020 a.u., P = 0.0003). Similar results were seen in the IBS-C ≥ 2 subpopulation (Active group: 3.14 ± 1.219 a.u. vs Placebo group: 2.59 ± 1.017 a.u., P = 0.0009).CONCLUSIONThis meta-analysis supports previous data linking S. cerevisiae I-3856 and improvement of GI symptoms, in IBS overall population and in the IBS-C and IBS-C ≥ 2 subpopulations.

show abstract

Randomized double blind placebo-controlled trial ofSaccharomyces cerevisiaeCNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation

Cited by 70 publications

References 28 publications

Effects ofSaccharomyces cerevisiaeorboulardiiyeasts on acute stress induced intestinal dysmotility

Effects ofSaccharomyces cerevisiaeorboulardiiyeasts on acute stress induced intestinal dysmotility

Dietary and pharmacological treatment of abdominal pain in IBS

Saccharomyces cerevisiaeCNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis

Contact Info

Product

Resources

About